Ribosome-inactivating proteins (RIPs) are rRNA N-glycosylases from plants (EC 3.2. 2.22)
that inactivate ribosomes thus inhibiting protein synthesis. The antiviral properties of RIPs …

The development of safe and efficacious enzyme-based human therapies has increased
greatly in the last decades, thanks to remarkable advances in the understanding of the …

To interfere with cell function, many scientists rely on methods that target DNA or RNA due to
the ease with which they can be applied. Proteins are usually the final executors of function …

Cancer is one of the most serious human diseases, causing millions of deaths worldwide
annually, and, therefore, it is one of the most investigated research disciplines. Developing …

Ribosome-inactivating proteins (RIPs) are N-glycosidases, which depurinate a specific
adenine residue in the conserved α-sarcin/ricin loop (α-SRL) of rRNA. This loop is important …

Ribosome-inactivating proteins (RIPs) are found in several edible plants and are well
characterized. Many studies highlight their use in cancer therapy, alone or as …

Immunotoxins are proteins that consist of a protein toxin conjugated to a specific targeting
moiety. The targeting moiety is usually an antibody or ligand, such as monoclonal antibody …

For the recombinant expression of toxin-based drugs, a crucial step lies not only in the
choice of the production host (s) but also in the accurate design of the protein chimera …

Ribosome-inactivating proteins (RIPs) are plant toxins that irreversibly damage ribosomes
and other substrates, thus causing cell death. RIPs are classified in type 1 RIPs, single-chain …

Simple Summary Antitumor therapy with immunotoxins is limited by problems of
immunogenicity and low efficacy in solid tumors. The different strategies to solve these …